Frances A Bennett

US Patent:

7488802, Feb 10, 2009

Filed:

Dec 22, 2003

Appl. No.:

10/741481

Inventors:

Mary Collins - Natick MA, US
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Vila Valge-Archer - Little Abington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Royston, GB

Assignee:

Wyeth - Madison NJ
MedImmune Limited - Cambridge

International Classification:

C07K 16/00
C07K 16/28
A61K 39/395

US Classification:

5303871, 5303881, 53038815, 53038822, 53038875, 4241301, 4241331, 4241351, 4241411, 4241421

Abstract:

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

US Patent:

7521051, Apr 21, 2009

Filed:

Dec 22, 2003

Appl. No.:

10/540084

Inventors:

Mary Collins - Natick MA, US
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abington, GB
John Andrews - Ware, GB
Caroline Russell - Royston, GB

Assignee:

MedImmune Limited - Cambridge
Wyeth - Madison NJ

International Classification:

A61K 39/395

US Classification:

4241441, 4241301, 4241411, 4241421, 4241431

Abstract:

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

US Patent:

8088905, Jan 3, 2012

Filed:

Mar 16, 2009

Appl. No.:

12/405058

Inventors:

Mary Collins - Natick MA, US
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abbington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Herts, GB

Assignee:

Wyeth - Madison NJ
MedImmune Limited

International Classification:

C12N 15/11

US Classification:

536 231

Abstract:

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

US Patent:

20080241130, Oct 2, 2008

Filed:

Mar 28, 2008

Appl. No.:

12/057778

Inventors:

Jill F. Wright - Ashland MA, US
Spencer C. Liang - Mountain View CA, US
Frances K. Bennett - Sudbury MA, US
Mary Collins - Natick MA, US
Beatriz M. Carreno - Clayton MO, US

International Classification:

A61K 39/395
G01N 33/557
A61K 38/17
A61P 11/06

US Classification:

4241301, 435 792, 514 2

Abstract:

The invention provides a novel mouse IL-17F/IL-17A, and further provides uses of such mouse IL-17F/IL-17A in the characterization of the IL-17F/IL-17A heterodimer. The present invention is also related to polynucleotides and polypeptides of the IL-17F/IL-17A signaling pathway, and targeting of the IL-17F/IL-17A signaling pathway in methods of treating IL-17F/IL-17A-associated disorders. The invention thus provides methods of using isolated IL-17F/IL-17A heterodimer, e.g., in a mouse model of airway inflammation, and specific or selective IL-17F/IL-17A modulators (e.g., signaling agonists or signaling antagonists (e.g., specific or selective antagonistic antibodies, specific or selective antagonistic small molecules, etc.)). The invention also provides methods of screening for compounds capable of modulating IL-17F/IL-17A biological activity, e.g., IL-17F/IL-17A signaling antagonists (e.g., using the mouse model of airway inflammation), as well as methods of identifying whether the IL-17F/IL-17A modulator is a specific IL-17F/IL-17A modulator. The invention is also directed to novel methods for diagnosing, prognosing, monitoring, preventing, and/or treating IL-17F/IL-17A-associated disorders, including, but not limited to, inflammatory disorders (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., airway inflammation, chronic obstructive pulmonary disease, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets identified by methods of screening of the invention, and uses of such identified therapeutics in methods of treatment and prevention of IL-17F/IL-17A-associated disorders.

US Patent:

20080311117, Dec 18, 2008

Filed:

Aug 17, 2007

Appl. No.:

11/893989

Inventors:

Mary Collins - Natick MA, US
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Royston, GB

International Classification:

A61K 39/395
A61P 35/00

US Classification:

4241331, 4241301, 4241391, 4241731

Abstract:

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.